Image
Icon

Directory

IconAssociations and Institutes
IconBBBEE Consulting and Verification Agencies
IconCompare Medical Scheme Benefits
IconConsumer Protection
IconCorporate Governance
IconCredit Bureaus
IconEmergency Medical Rescue
IconExpatriate Cover
IconHealthcare Consultants
IconMedical Aid Brokers
IconMedical Aid Schemes
IconMedical Schemes Trustees Liability Insurance
IconMedical Service Providers
IconOmbud
IconOnline Quotes
IconPublications
IconRegulatory Authorities
IconWellness Programs
Image
  Subscribe To »

Novartis – pioneering the way forward in the treatment of NCDs

Published

2017

Mon

31

Jul

  • 4 out of top 10 leading causes of death in SA are due to NCDs
  • 17 biosimilar medicines from Novartis in the pipeline to fight NCDs in SA
Johannesburg: In South Africa, two out of every five deaths can be attributed to non-communicable diseases (NCDs) and injuries; 40 percent of deaths among men, and 29 percent among women are premature and before the age of 60. Over 40 percent of the population suffers from high blood pressure, and over ten percent has high blood glucose, increasing the risk for diabetes.
 
The NCDs causing the highest number of deaths in SA are cardiovascular diseases (18%), cancer (7%), respiratory diseases (4%), diabetes (2%) and other NCDs such as asthma and cataracts (9%).
 
While NCDs are the leading causes of death globally, SA is still battling the HIV/AIDS and TB epidemics, which top the mortality lists. But NCDs are fast catching up and more and more South Africans are becoming ill and dying from these diseases. NCDs make up four of the top 10 causes of death in South Africa – and these numbers are on the rise, according to Statistics South Africa.
 
However, it’s not all doom and gloom as much progress has been made in this area. In an effort to overcome the plight of NCDs in South Africa, pharmaceutical company Novartis, has been one of the pioneers in the area of NCDs through its wide portfolio of biologic and biosimilar treatments and the company continually conducts research to discover other breakthrough medicines in this regard.
 
Three things that can help combat the plight of NCDs include: the reduction of underlying risk factors (tobacco use, physical inactivity, unhealthy diets, and harmful use of alcohol), early detection, and timely treatments.
 
It is in the last of the three, namely timely treatments, that the use of biologics and biosimilars can make such a huge difference to South Africans.
 
The role of biologics and biosimilar treatments
 
Biologics are made using human or animal proteins – a complicated and lengthy process. They do something which normal medications cannot do, namely block specific interactions in the immune system, and so are able to fight diseases in a new and effective manner.
 
Biologics are particularly effective in treating inflammation, auto-immune diseases, cancer, cardiovascular diseases and metabolic conditions; all of which are on the rise in South Africa.
 
A substantial amount of time and research goes into developing biologics and there are strict guidelines to which these medicines must adhere, making their timeframe for entry to market that much longer. However, biosimilars, which are similar to existing biological medicines, are already approved for use, and have specifically been developed to make quick and affordable access to treatments by more South Africans a reality.
 
Novartis was the first to develop and launch biosimilars in every major region of the world.
 
There are currently eleven biosimilar medicines in the pipeline from Novartis, with six more to follow in 2018.
 
“Sandoz, Novartis’ generic and biosimilar pharmaceutical division, has decades of experience in pharmaceutical biotechnology and is recognised as a worldwide pioneer and leader in the production of biosimilars, which are safe, effective, high quality and affordable versions of existing biological medicines,” says Dr Thomas Kowallik, CEO and Country President of Novartis SA.
 
Part of the SA government’s plan to combat the rising number of deaths from NCDs lies in the cost-effective management (by treatment) of high-risk individuals, and it is here that the biosimilars made available by Novartis can save a huge number of lives in SA.
 
Source: Bespoke Strategic Communications
 
« Back to previous page Print this page » |
 

Breaking News »

So, you are thinking of having that baby…

By Marlise Kotze, Financial Planner at Alexander Forbes Retail I just came back from maternity leave with my second child in January. I know most people will warn you about the sleepless nights, vomits ...
Read More »

  

Understanding supplementary medical services

By Cape Medical Plan Supplementary services, like any medical service you receive, are often subject to an authorisation process. Although this might seem frustrating, it is implemented to protect both your ...
Read More »

  

Dialogue, HIV testing campaign targets men, boys

Deputy President Cyril Ramaphosa will on Thursday participate in the launch of the Religious Leaders’ Dialogue Series and HIV Testing Services Campaign in Soshanguve, north of Pretoria. The Deputy President ...
Read More »

  

BHF announces new Managing Director

          Dr Katlego Mothudi, Managing Director Board of Healthcare Funders of Southern Africa                   The ...
Read More »

 

More News »

Image

Investment »

Image

Life »

Image

Retirement »

Image

Short-term »

Advertise Here
Image
Advertise Here

From The Glossary »

Icon

Gold Funds:

Gold funds seek capital appreciation by investing in gold mining shares. They may be more volatile than funds invested in many sectors. The benchmark is the JSE Gold Index.
More Definitions »

 
 
By using this website you agree to the Terms of Use.
Copyright © Stoker Risk & ICT (Pty) Ltd 2004 - 2017.
All Rights Reserved.
Icon

Advertise

  Icon

eZine

  Icon

Contact IG

Icon

Media Pack

  Icon

RSS Feeds